摘要
IL-6在类风湿关节炎（RA）、幼年特发性全身性关节炎（sJIA）、Castleman病、系统性红斑狼疮（SLE）等多种风湿免疫性疾病发生、进展过程中均有过量表达,且发挥关键作用.Tolicizumab是第一个人源性的IL-6R抗体,通过特异性识别结合IL-6R而阻断IL-6生物学活性,发挥抑制上述疾病炎症反应的作用.大量研究结果证实,tocilizumab不仅能明显缓解RA的临床症状,而且能防止关节继续破坏.此外,tocilizumab在治疗全身性和关节型sJIA、Castleman病、SLE、克罗恩病等风湿免疫性疾病也获得了巨大的成功.
Over-production of interleukin-6 （IL-6） plays an essential role in rheumatic autoimmune diseases such as rheumatoid arthritis （RA）,juvenile idiopathic arthritis （JIA）and systemic lupus erythematosus （SLE）.Tocilizumab,the first humanized anti-human IL-6 receptor antibody,can bind IL-6R by specific recognition and subsequently block the biological activity of IL-6.A large number of studies have demonstrated that tocilizumab was effective not only in improving clinical manifestation but also in preventing joint destruction of RA.In addition,A great successs has been made in the treatment of systemic and articular types of JIA,Castleman＇s disease,SLE,Crohu＇s disease,etc,by the application of tolicizubmab.
出处
《国际免疫学杂志》
CAS
2013年第5期363-367,共5页
International Journal of Immunology
基金
深圳市科技计划项目（201002067）
